R1 RCM Stock Forecast, Price & News

R1 RCM (NASDAQ:RCM) Frequently Asked Questions

Is R1 RCM a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" R1 RCM stock.
View analyst ratings for R1 RCM or view top-rated stocks.

How has R1 RCM's stock price been impacted by Coronavirus?

R1 RCM's stock was trading at $10.16 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RCM stock has increased by 148.9% and is now trading at $25.29.
View which stocks have been most impacted by COVID-19.

When is R1 RCM's next earnings date?

R1 RCM is scheduled to release its next quarterly earnings announcement on Thursday, February 17th 2022.
View our earnings forecast for R1 RCM.

How were R1 RCM's earnings last quarter?

R1 RCM Inc. (NASDAQ:RCM) released its earnings results on Tuesday, November, 2nd. The healthcare provider reported $0.05 earnings per share for the quarter, missing analysts' consensus estimates of $0.08 by $0.03. The healthcare provider had revenue of $379.70 million for the quarter, compared to analysts' expectations of $372.87 million. R1 RCM had a trailing twelve-month return on equity of 40.83% and a net margin of 9.96%.
View R1 RCM's earnings history.

What guidance has R1 RCM issued on next quarter's earnings?

R1 RCM updated its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.46 billion-$1.48 billion, compared to the consensus revenue estimate of $1.47 billion.

What price target have analysts set for RCM?

9 analysts have issued 1-year price targets for R1 RCM's shares. Their forecasts range from $27.00 to $35.00. On average, they expect R1 RCM's stock price to reach $29.38 in the next year. This suggests a possible upside of 16.2% from the stock's current price.
View analysts' price targets for R1 RCM or view top-rated stocks among Wall Street analysts.

Who are R1 RCM's key executives?

R1 RCM's management team includes the following people:

• Joseph Gerard Flanagan, President, Chief Executive Officer & Director
• John Sparby, COO, Executive VP-Operations & Delivery (LinkedIn Profile)
• Rachel Wilson, Chief Financial Officer, Treasurer & Executive VP
• Julia K. Davis, Chief Information Officer & Executive VP
• Jay Sreedharan, Chief Technology & Digital Officer

What is Joseph Flanagan's approval rating as R1 RCM's CEO?

253 employees have rated R1 RCM CEO Joseph Flanagan on Glassdoor.com. Joseph Flanagan has an approval rating of 70% among R1 RCM's employees.

Who are some of R1 RCM's key competitors?

Some companies that are related to R1 RCM include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), AMN Healthcare Services (AMN), Amedisys (AMED), LHC Group (LHCG), CorVel (CRVL), MEDNAX (MD), Tivity Health (TVTY) and Cross Country Healthcare (CCRN).
View all of RCM's competitors.

What other stocks do shareholders of R1 RCM own?

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.com (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

What is R1 RCM's stock symbol?

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

Who are R1 RCM's major shareholders?

R1 RCM's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.47%), Capital World Investors (2.14%), American Century Companies Inc. (1.31%), Bank of New York Mellon Corp (1.18%), Eaton Vance Management (1.17%) and Wellington Management Group LLP (1.13%). Company insiders that own R1 RCM stock include Achi Series Lllp Tcp-Asc, Albert Rene Zimmerli, Alex Mandl, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan, Michael C Feiner and Richard B Jr Evans.
View institutional ownership trends for R1 RCM.

Which major investors are selling R1 RCM stock?

RCM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Pura Vida Investments LLC, Allianz Asset Management GmbH, Two Sigma Investments LP, Royal Bank of Canada, Geode Capital Management LLC, Morgan Stanley, and American Century Companies Inc.. Company insiders that have sold R1 RCM company stock in the last year include Achi Series Lllp Tcp-Asc, Alex Mandl, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan, and Richard B Jr Evans.
View insider buying and selling activity for R1 RCM or view top insider-selling stocks.

Which major investors are buying R1 RCM stock?

RCM stock was bought by a variety of institutional investors in the last quarter, including Eaton Vance Management, Sunriver Management LLC, Wellington Management Group LLP, Boston Partners, Voya Investment Management LLC, Polar Capital Holdings Plc, Goldman Sachs Group Inc., and Point72 Asset Management L.P.. Company insiders that have bought R1 RCM stock in the last two years include Albert Rene Zimmerli, and Joseph Gerard Flanagan.
View insider buying and selling activity for R1 RCM or or view top insider-buying stocks.

How do I buy shares of R1 RCM?

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is R1 RCM's stock price today?

One share of RCM stock can currently be purchased for approximately $25.29.

How much money does R1 RCM make?

R1 RCM has a market capitalization of $7.02 billion and generates $1.27 billion in revenue each year. The healthcare provider earns $117.10 million in net income (profit) each year or ($2.01) on an earnings per share basis.

How many employees does R1 RCM have?

R1 RCM employs 20,200 workers across the globe.

Does R1 RCM have any subsidiaries?

The following companies are subsidiares of R1 RCM: Accretive Health Mauritius Inc., Advanced Data Processing Inc., Cerner RevWorks, Intermedix, Intermedix ARM LLC, Intermedix Analytics LLC, Intermedix Corporation, Intermedix Holdings Inc., Intermedix Lietuva UAB, Intermedix Midco Inc., Intermedix Office Based LLC, Intermedix Physician Services LLC, Intermedix Staffing Inc., Med Media Inc., Medical Consultants Inc., Optima (NZ) Limited, Optima (US) LTD, Practice Support Resources LLC, Project Links Parent Inc., R1 RCM Global Private Limited, R1 RCM India Private Limited, Rover16 Inc., SCI Solutions, The DeZonia Group Inc., The Optima Corporation (International) LTD, The Optima Corporation Limited, and The Optima Corporation PTY LTD.

When was R1 RCM founded?

R1 RCM was founded in 2003.

What is R1 RCM's official website?

The official website for R1 RCM is www.r1rcm.com.

Where are R1 RCM's headquarters?

R1 RCM is headquartered at 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611.

How can I contact R1 RCM?

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at (312) 324-7820, via email at [email protected], or via fax at 302-655-5049.